| Basics |
Cel-Sci Corporation
CEL-SCI Corp is a biotechnology company. It is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.
|
| IPO Date: |
December 1, 1984 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$21.37M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 4.91%
|
| Avg Daily Range (30 D): |
$0.02 | 8.04%
|
| Avg Daily Range (90 D): |
$0.02 | 6.58%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.82M |
| Avg Daily Volume (30 D): |
1.24M |
| Avg Daily Volume (90 D): |
1.16M |
| Trade Size |
| Avg Trade Size (Sh.): |
477 |
| Avg Trade Size (Sh.) (30 D): |
499 |
| Avg Trade Size (Sh.) (90 D): |
575 |
| Institutional Trades |
| Total Inst.Trades: |
350 |
| Avg Inst. Trade: |
$1.45M |
| Avg Inst. Trade (30 D): |
$.69M |
| Avg Inst. Trade (90 D): |
$.69M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.6M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
148.4K |
|
|
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
|
|
|
|
Diluted EPS
|
$-.41
|
$-.08
|
$-.1
|
|
Revenue
|
$ .03M
|
$ -.18M
|
$ -.17M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -68.23M
|
$ -6.57M
|
$ -7.07M
|
|
Operating Income / Loss
|
$ -26.08M
|
$ -6.39M
|
$ -6.89M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -3.39M
|
$
|
$
|
|
PE Ratio
|
|
|
|
| Splits |
| Jun 15, 2017:
25:1
|
| Sep 25, 2013:
10:1
|
|
